Presentations at the 2023 EULAR European Congress of Rheumat

-- Only Sjögren’s syndrome Phase 2 trial to meet the primary endpoint in both patient population types --


-- Patients with moderate-to-severe systemic disease activity treated with... | May 31, 2023

Related Keywords

Milan , Lombardia , Italy , South Hall , Argyll And Bute , United Kingdom , Elizabethhz Thompson , , Linkedin , Newcastle University , Facebook , European Congress , Nasdaq , Twitter , Instagram , Company Phase , Clinical Research Institute , Horizon Therapeutics , Moderate To Severe Systemic Disease , Syndrome Disease Activity Index , Concept Study , Session Room , Syndrome Patient Reported Index , Biomarker Analysis , Reduces Blood Biomarkers , Poster Hall , Syndrome Trial , Horizon Therapeutics Public Limited Company Stock Exchange , News , Information , Press Release , Only , Yndrome , Hase , Trial , O , Feet , The , Primary , Ndpoint , N , Moth , Patient , Population , Types , Patients , Ith , Systemic , Disease , Activity , Reated Hznp Ie00bqpvqz61 ,